Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
about
Systemic Chemotherapy in Advanced Pancreatic CancerGenetic factors affecting patient responses to pancreatic cancer treatmentAnti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerA prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancerA Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic CancerEfficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trialsRecent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Targeting cancers in the gastrointestinal tract: role of capecitabineMaintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinomaA phase I study of an oral simulated FOLFOX with high dose capecitabine.First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Pancreatic adenocarcinomaOpioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancerCapecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreasBosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyCapecitabine: fulfilling the promise of oral chemotherapy.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.Systemic therapy for metastatic pancreatic adenocarcinoma.Recent developments in the pharmacological treatment of advanced pancreatic cancer.Advanced pancreatic cancer: is there a role for combination therapy?Review article: chemotherapy for pancreatic cancer.Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.Emerging drugs in pancreatic cancer.Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.Adjuvant and neoadjuvant treatment in pancreatic cancerCapecitabine: effective oral fluoropyrimidine chemotherapy.Capecitabine in carcinoma of the pancreas.A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerGemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic CancerPancreatic cancer--is the wall crumbling?Gemcitabine in the treatment of metastatic pancreatic cancer.First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues.Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.Safety of capecitabine: a review.
P2860
Q26750440-2AD13501-57C8-4D68-8DC0-48A7FF1C25A0Q28075293-65C48182-5D82-4C44-8897-AAA4F46C5220Q28534413-9FD6C3B3-BB37-49DD-BB55-AE6D8A2C5CD3Q33398693-261C9407-8249-42E6-92EA-0ED51DE0C9D7Q33402374-A73D952D-C78F-49FF-88B3-DDE8546550EEQ33416894-EC77ACD0-7CEC-4AFA-BD81-0C5313F6F971Q33632330-E57C56B8-97CB-4042-8045-AE26A3421CA1Q33916021-58607848-3CC3-4E9D-85EE-231324AD40ADQ33967458-5133CB6D-0AFE-4A0C-97EA-3C6EB5C79802Q33973344-06C74740-DD76-4894-BE84-C1A26A4DDE7CQ34008520-2321B0DD-330F-4D46-97E5-333E92BA1ACFQ34129346-D472FBB4-2D42-4D60-A486-6121E56FD191Q34140498-D0A7FE5C-9CE1-4F70-8677-DE2AD2499F36Q34161303-F3018414-640A-4F76-9CD2-A80C86611A3FQ34449812-A5994DBC-C5DB-44BD-A5BC-B453C8D74CB1Q34658293-C5102BAA-E7E9-4149-AEF7-FC23E9062F10Q34660785-4F611FFB-868A-4B95-8BE3-98FFF59999F3Q34818494-EC659AA5-7D7E-49A9-9251-3A0C166F3313Q35032865-E1BFAA60-950D-41EA-BBDD-B2CAB1A4064CQ35076238-D7C73F3E-37EF-427C-97E1-0EDECB49D0D2Q35144004-8C49FE46-A96E-4EB3-83DD-F8C02192FF24Q35576200-5CB65717-2A35-4CED-9EF0-82D0DDC99B8CQ35599597-BBC395D3-2BF5-4D2D-863B-41CFE82B531BQ35638434-E959FCD8-B9DA-45BF-8EA6-04C8BC56E3F7Q35779283-6438B466-B6A0-4FBF-968F-711600057DA6Q35832274-34B72D88-C177-4BE5-8F08-1F268DD4FB16Q35886631-22708C2C-838B-460F-B726-0CED504F3EB3Q36164013-8F51F5BA-931B-46F2-A21B-FFE4C91831ECQ36548730-99A73BDF-60AF-4BAA-92A9-03E96FC83728Q36557467-BF36B82A-D5C9-48BE-910D-6659A0923D78Q36612255-57E0172A-1C68-4F55-B85E-DC21943F3E7DQ36615091-F29A8EE4-A553-4570-932F-E8C127E9F886Q36616386-02AD354C-AE50-40AF-BED1-2BCA2B87A249Q37009734-DE5EC399-E2AC-4B28-A1CF-BF7FAE0199E8Q37125325-62BDD804-D22A-4AAB-9CA1-AA57243F70D5Q37134412-70861335-72AE-4370-B884-E6A7B59261DEQ37140954-AE5D9721-C8A9-4392-951C-17CD1C7140FAQ37270388-F0FF829E-E1A2-42F1-AA22-0812976854D7Q37696059-6F79FC4F-7663-43F9-B1EF-F5E55AE855DCQ37781051-9A18FD1E-7141-4D30-B7A9-93276F31E6DF
P2860
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@en
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@nl
type
label
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@en
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@nl
prefLabel
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@en
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@nl
P2093
P356
P1476
Phase II study of oral capecit ...... metastatic pancreatic cancer.
@en
P2093
Allen Cohn
Jerry A Varkey
John V Cox
Joseph J Schulz
Ted P Szatrowski
Thomas H Cartwright
Yin-Miao Chen
P304
P356
10.1200/JCO.20.1.160
P407
P577
2002-01-01T00:00:00Z